CD8A and melanoma: Given the relevance of M-MDSCs as predictive biomarkers for response to Ipilimumab, Kitano et al. proposed a computational algorithm-driven analysis of PBMCs, demonstrating that melanoma patients with a pre-treatment M-MDSC frequency lower than 14.9% had a significantly longer OS and that M-MDSC levels inversely correlated with peripheral CD8+ T cell expansion following Ipilimumab treatment (56).